MDT - Medtronic's Latest Generation Of Transcatheter Aortic Valve Replacement Implant Passes FDA's Muster Shares Gain | Benzinga
Wednesday, the FDA approved Medtronic plc’s (NYSE:MDT) Evolut FX+ transcatheter aortic valve replacement (TAVR) system for symptomatic severe aortic stenosis.
The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
The Evolut FX+ TAVR system offers larger coronary access windows through a modified diamond-shaped frame design, which is four times larger than previous iterations of the Evolut TAVR system.
Evolut FX+ provides increased space for catheter maneuverability to facilitate access to coronary arteries of varying patient anatomies.
Severe aortic stenosis occurs when ...